iBio, Inc. Files Definitive Proxy Statement

Ticker: IBIO · Form: DEF 14A · Filed: 2024-10-10T00:00:00.000Z

Sentiment: neutral

Topics: proxy-statement, governance, shareholder-meeting

Related Tickers: IBIO

TL;DR

IBIO proxy filed - shareholders vote on directors & pay soon.

AI Summary

iBio, Inc. filed its definitive proxy statement on October 10, 2024, for its annual meeting. The filing details the company's governance, executive compensation, and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of auditors, with specific financial details and executive compensation packages to be elaborated within the full document.

Why It Matters

This filing is crucial for shareholders as it outlines the company's leadership, compensation structures, and the key decisions they will vote on, directly impacting the company's future direction and governance.

Risk Assessment

Risk Level: medium — Proxy statements can reveal significant information about executive compensation, potential shareholder activism, and upcoming strategic decisions that may impact stock price.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this DEF 14A filing by iBio, Inc.?

The primary purpose is to provide shareholders with information for the upcoming annual meeting, including details on director nominations, executive compensation, and other corporate governance matters, allowing them to vote on these items.

When was this definitive proxy statement filed with the SEC?

This definitive proxy statement was filed with the SEC on October 10, 2024.

What is the Central Index Key (CIK) for iBio, Inc.?

The Central Index Key (CIK) for iBio, Inc. is 0001420720.

What is the Standard Industrial Classification (SIC) code for iBio, Inc.?

The Standard Industrial Classification (SIC) code for iBio, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

What were iBio, Inc.'s former company names and when did they change?

iBio, Inc. was formerly known as iBioPharma, Inc. (name change on 20080806) and InB:Biotechnologies, Inc. (name change on 20071210).

Filing Stats: 4,700 words · 19 min read · ~16 pages · Grade level 11.9 · Accepted 2024-10-10 16:10:53

Key Financial Figures

Filing Documents

Executive Compensation

Executive Compensation 27 Pay vs. Performance 37

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 41 Transactions With Related Persons, Promoters and Certain Control Persons 44 Additional Information About These Proxy Materials and Voting 47 Annual Report on Form 10-K 53 Notice Regarding Delivery of Stockholder Documents ("Householding" Information) 54 Stockholder Proposals for the 2025 Annual Meeting 55 Other Matters 56 Proxy Statement 1 Table of Contents Proxy Summary PROXY Summary Directors and Director Nominees Name and Position Age Director Since Independent Committee Memberships Audit Compensation Nominating & Corporate Governance Science & Technology MARTIN BRENNER Chief Executive Officer and Chief Scientific Officer of iBio 54 June 2024 WILLIAM D. CLARK President and Chief Executive Officer of Vibrant Biomedicines, Inc. 56 August 2021 DR. ALEXANDRA KROPOTOVA Executive Vice President and Chief Medical Officer of SAb Biotherapeutics 52 October 2020 EVERT SCHIMMELPENNINK Chief Executive Officer and President of LENZ Therapeutics, Inc. 52 April 2019 GARY SENDER Former Chief Financial Officer of Nabriva Therapeutics plc 62 October 2020 DAVID ARKOWITZ Former Chief Financial Officer and Head of Business Development of Seres Therapeutics, Inc. 63 ANT NIO PARADA C hief Executive Officer of FairJourney Biologics 56 Chair Member Chair of the Board of Directors 2 iBio, Inc. Table of Contents Proposal 1 Election of Directors PROPOSAL 1 Election of Directors The Board of Directors currently consists of six (6) directors and is divided into three classes. Each class serves for a term ending at the third annual meeting of stockholders following the election of such class, with the terms of office of the respective classes expiring in successive years. Directors in Class I will stand for election this year at the 2024 Annual Meeting, directors in Class II will stand for election at the 2025 Annual Meet

View on Read The Filing